Range Impact Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Range Impact Inc (RNGE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Range Impact Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 78,236M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-6.8% annualized vs trailing 12 months), vs decelerating (-8.0%) for its tracked peer group.
- Growth: Range Impact Inc generated 31.6% revenue growth year over year in Q1 2026, vs 5.6% for its tracked competitors combined.
- Profitability: Its -200.3% net margin compares with 18.3% for the peer group.
- Peer revenue share: Range Impact Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.39M compares with $0.84M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RNGE Sales vs. its Competitors, Q1 2026
Range Impact Inc reported revenue growth of 31.58 % year on year in Q1 2026, above its competitors' combined revenue growth of 5.60 %.
With a net margin of -200.32 %, Range Impact Inc reported lower profitability than its competitors (18.26 %).
Range Impact Inc generated 0.01 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Range Impact Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Range Impact Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Range Impact Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Range Impact Inc's competitor groups requires a Commercial License.
For context: the Construction Services industry grew revenue 27.3% year over year, combined, vs 31.6% for Range Impact Inc. Range Impact Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Range Impact Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Range Impact Inc | - | No | No | No |
| Competitors combined (5) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) | 12.50 % (1 of 8) | 85.70 % (6 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RNGE Stock Performance relative to its Competitors
RNGE Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Jazz Pharmaceuticals Plc | 282.9% | Outperformed |
| 2 | Biogen Inc | 282.9% | Outperformed |
| 3 | Pfizer Inc | 282.9% | Outperformed |
| 4 | Novartis Ag | 282.9% | Outperformed |
| 5 | Corbus Pharmaceuticals Holdings Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Range Impact Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Range Impact Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Range Impact Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Range Impact Inc | 77.67 | 3.93 |
| Novartis Ag | 278,724.35 | 56,674.00 |
| Pfizer Inc | 162,592.47 | 63,696.00 |
| Biogen Inc | 33,520.59 | 9,937.40 |
| Jazz Pharmaceuticals Plc | 16,067.49 | 4,601.23 |
| Corbus Pharmaceuticals Holdings Inc | 132.36 | 1.54 |
| SUBTOTAL | 491,114.93 | 134,914.10 |
Sources: Range Impact Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Range Impact Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Range Impact Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis Ag | Named by the company | 85% |
| Biogen Inc | Named by the company | 85% |
| Jazz Pharmaceuticals Plc | Named by the company | 85% |
| Pfizer Inc | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Zynerba Pharmaceuticals Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Range Impact Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Range Impact Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Biogen Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Range Impact Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Range Impact Inc | 78 | 393,039 | 1,223,436 |
| Novartis Ag | 278,724 | 752,973 | 185,566 |
| Pfizer Inc | 162,592 | 849,280 | 58,267 |
| Biogen Inc | 33,521 | 1,324,987 | 182,920 |
| Jazz Pharmaceuticals Plc | 16,067 | 1,592,122 | 325,524 |
| Corbus Pharmaceuticals Holdings Inc | 132 | 42,775 | -2,830,639 |
| PEERS TOTAL | 491,037 | 839,552 | 127,870 |
Range Impact Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 58.91 % |
| Jazz Pharmaceuticals Plc | United States 89.79 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Range Impact Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 48 companies in Range Impact Inc's industry classification, broader than the peer set above. Market cap in millions of $.Range Impact Inc ranks #0 of 48 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,726, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Hca Healthcare Inc | 96,721 | 38.50 % |
| 2 | Tenet Healthcare Corp | 21,458 | 8.54 % |
| 3 | Fresenius Medical Care Ag | 13,034 | 5.19 % |
| 4 | Brightspring Health Services Inc | 12,501 | 4.98 % |
| 5 | Encompass Health Corporation | 1,234 | 5.2% |
| 6 | Davita Inc | 1,234 | 5.2% |
| 7 | Universal Health Services Inc | 1,234 | 5.2% |
| 8 | Ensign Group Inc | 1,234 | 5.2% |
| 9 | Hims and Hers Health Inc | 1,234 | 5.2% |
| 10 | Pacs Group Inc | 1,234 | 5.2% |
| 0 | Range Impact Inc | 6 | 0.00 % |
Market cap and industry share for the rest of Range Impact Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2016-07-19.
Range Impact Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Construction Services industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (92 companies). See the full Construction Services industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 8.06 % | 22.76 % (avg) | -14.7 pp |
| Operating Margin | -66.05 % | industry median | -73.5 pp |
| EBITDA Margin | - | 4.32 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.00 % | 4.50 % (avg) | -4.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Range Impact Inc's Valuation vs Competitive Position
Valuation multiples vs the Construction Services industry average (92 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Construction Services industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 1.5x | 28.7x | -27.2x |
| EV / EBITDA | 1.3x | 17.9x | -16.6x |
| P/B | 0.9x | 4.4x | -3.5x |
| Return on Equity | 57.15 % | industry aggregate | 17.74 % |
| Return on Invested Capital | -2.23 % | 6.65 % (avg) | -8.88 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Range Impact Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | -54.28 % |
| Operating Margin | - | - | - | - | -43.62 % | -36.44 % |
| Return on Invested Capital | -191.87 % | -137.33 % | -21.72 % | - | -25.84 % | -1.52 % |
| P/E | - | - | - | - | - | 0.9x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Range Impact Inc's Strategic Group Map
Every company in Range Impact Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Range Impact Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Range Impact Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,726 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 4.50 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Range Impact Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Range Impact Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Range Impact Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Range Impact Inc falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Range Impact Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 17.7 points above the industry aggregate.
Weaknesses
- Operating margin 73.5 points below the industry median.
- Latest-quarter revenue run-rate is decelerating (-6.8% annualized vs trailing 12 months).
Opportunities
No rule matched.
Threats
- Industry dominated by Hca Healthcare Inc , holding 38.50 % of industry market cap.
- Tracked peer group's revenue run-rate is broadly decelerating (-8.0% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Range Impact Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Range Impact Inc | 0.24 | 0.46 | 0.09 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Biogen Inc | - | 2.74 | 0.35 |
| Jazz Pharmaceuticals Plc | 0.75 | 1.83 | 1.22 |
| Corbus Pharmaceuticals Holdings Inc | 1.35 | 6.99 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Range Impact Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Range Impact Inc | Q1 2026 | +31.6 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Biogen Inc | Q1 2026 | +1.9 % | +32.8 % |
| Jazz Pharmaceuticals Plc | Q2 2026 | +15.5 % | - |
| Corbus Pharmaceuticals Holdings Inc | Q2 2026 | - | - |
| PEERS TOTAL | +7.9 % | -1.2 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Range Impact Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Range Impact Inc | Q1 2026 | - | - |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Biogen Inc | Q1 2026 | +5.0 % | +8.7 % |
| Jazz Pharmaceuticals Plc | Q2 2026 | - | +39.6 % |
| Corbus Pharmaceuticals Holdings Inc | Q2 2026 | - | - |
Range Impact Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Range Impact Inc | 13.56% | 12.86% | 57.15% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Biogen Inc | 4.71% | 5.24% | 7.54% |
| Jazz Pharmaceuticals Plc | 8.19% | 10.06% | 21.37% |
| Corbus Pharmaceuticals Holdings Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Range Impact Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Range Impact Inc | 6.28 | 19.76 |
| Novartis Ag | 19.93 | 4.92 |
| Pfizer Inc | 37.41 | 2.55 |
| Biogen Inc | 24.23 | 3.37 |
| Jazz Pharmaceuticals Plc | 15.83 | 3.49 |
| Corbus Pharmaceuticals Holdings Inc | - | 85.95 |
| PEERS AVERAGE | 23.89 | 3.64 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.